NASDAQ:KALV KalVista Pharmaceuticals (KALV) Stock Price, News & Analysis $12.34 -0.53 (-4.12%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$12.23▼$13.1450-Day Range$11.51▼$15.3952-Week Range$7.21▼$16.88Volume234,664 shsAverage Volume502,227 shsMarket Capitalization$520.60 millionP/E RatioN/ADividend YieldN/APrice Target$26.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get KalVista Pharmaceuticals alerts: Email Address KalVista Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.33 Rating ScoreUpside/Downside110.7% Upside$26.00 Price TargetShort InterestBearish13.46% of Shares Sold ShortDividend StrengthN/ASustainability-0.79Upright™ Environmental ScoreNews Sentiment0.75Based on 13 Articles This WeekInsider TradingSelling Shares$368,563 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.57) to ($1.61) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.08 out of 5 starsMedical Sector159th out of 910 stocksPharmaceutical Preparations Industry62nd out of 426 stocks 3.7 Analyst's Opinion Consensus RatingKalVista Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKalVista Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about KalVista Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.46% of the outstanding shares of KalVista Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKalVista Pharmaceuticals has a short interest ratio ("days to cover") of 17.9, which indicates bearish sentiment.Change versus previous monthShort interest in KalVista Pharmaceuticals has recently decreased by 5.02%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldKalVista Pharmaceuticals does not currently pay a dividend.Dividend GrowthKalVista Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKalVista Pharmaceuticals has received a 72.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for KalVista Pharmaceuticals is -0.79. Previous Next 2.6 News and Social Media Coverage News SentimentKalVista Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for KalVista Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KALV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, KalVista Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $368,563.00 in company stock.Percentage Held by Insiders12.30% of the stock of KalVista Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about KalVista Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for KalVista Pharmaceuticals are expected to grow in the coming year, from ($3.57) to ($1.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of KalVista Pharmaceuticals is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of KalVista Pharmaceuticals is -3.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalVista Pharmaceuticals has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about KalVista Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss Ratings“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.Learn these 4 simple steps and protect your savings before it’s too late. About KalVista Pharmaceuticals Stock (NASDAQ:KALV)KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.Read More KALV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KALV Stock News HeadlinesAugust 28, 2024 | insidertrades.comPaul K. Audhya Sells 2,135 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) StockAugust 22, 2024 | insidertrades.comInsider Selling: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells 7,102 Shares of StockSeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...August 22, 2024 | insidertrades.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $170,722.15 in StockSeptember 6 at 7:36 PM | finance.yahoo.comKalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024September 6 at 7:36 PM | markets.businessinsider.comBuy Rating for KalVista Pharmaceuticals Amid Positive Regulatory Developments and Strong Financial PositionSeptember 6 at 7:36 PM | markets.businessinsider.comBuy Rating Affirmed for KalVista Pharmaceuticals Amid Strong Prospects for Lead Drug Candidate, SebetralstatSeptember 5 at 4:20 PM | seekingalpha.comKalVista Pharmaceuticals: Looking To Be A Major Player In HAESeptember 7, 2024 | Behind the Markets (Ad)NASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...September 3, 2024 | finance.yahoo.comKalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaSeptember 3, 2024 | americanbankingnews.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest UpdateAugust 30, 2024 | americanbankingnews.comKalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Expected to Earn FY2025 Earnings of ($3.44) Per ShareAugust 18, 2024 | ca.finance.yahoo.comKALV Sep 2024 10.000 putAugust 15, 2024 | finance.yahoo.comKalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaAugust 11, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn SituationJuly 25, 2024 | bizjournals.comDrug developer ditches Cambridge for Framingham and triples its spaceJune 24, 2024 | seekingalpha.comBullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 LaunchJune 18, 2024 | businesswire.comKalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary AngioedemaSee More Headlines Receive KALV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for KalVista Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/05/2024Today9/07/2024Next Earnings (Estimated)12/05/2024Fiscal Year End4/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KALV CUSIPN/A CIK1348911 Webwww.kalvista.com Phone857-999-0075Fax866-553-3269Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$26.00 High Stock Price Target$32.00 Low Stock Price Target$20.00 Potential Upside/Downside+110.7%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,640,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-92.28% Return on Assets-78.12% Debt Debt-to-Equity RatioN/A Current Ratio9.90 Quick Ratio9.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book2.54Miscellaneous Outstanding Shares42,188,000Free Float36,999,000Market Cap$520.60 million OptionableOptionable Beta0.91 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesMr. Benjamin L. Palleiko (Age 58)CEO & Director Comp: $707.1kDr. Christopher M. Yea Ph.D. (Age 60)Chief Development Officer Comp: $640.23kDr. Edward P. Feener Ph.D. (Age 64)Chief Scientific Officer Comp: $506kMr. Ryan BakerHead of Investor RelationsMr. Brian Krex J.D. (Age 56)General Counsel Jarrod AldomVice President of Corporate CommunicationsMs. Rachel M. MortenSenior Vice President of Regulatory Affairs & QADr. Michael D. Smith Pharm.D. (Age 44)Senior Vice President of Development Dr. Paul K. Audhya M.B.A. (Age 51)M.D., Chief Medical Officer Ms. Nicole Sweeny (Age 48)Chief Commercial Officer More ExecutivesKey CompetitorsAlimera SciencesNASDAQ:ALIMArbutus BiopharmaNASDAQ:ABUSBeyondSpringNASDAQ:BYSIMagenta TherapeuticsNASDAQ:MGTABioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInsiders & InstitutionsPaul K AudhyaSold 2,135 sharesTotal: $26,474.00 ($12.40/share)Benjamin L PalleikoSold 14,215 sharesTotal: $170,722.15 ($12.01/share)Christopher YeaSold 7,102 sharesTotal: $85,295.02 ($12.01/share)Driehaus Capital Management LLCSold 5,821 shares on 8/16/2024Ownership: 1.270%Susquehanna Fundamental Investments LLCBought 52,347 shares on 8/15/2024Ownership: 0.162%View All Insider TransactionsView All Institutional Transactions KALV Stock Analysis - Frequently Asked Questions How have KALV shares performed this year? KalVista Pharmaceuticals' stock was trading at $12.25 on January 1st, 2024. Since then, KALV stock has increased by 0.7% and is now trading at $12.34. View the best growth stocks for 2024 here. How were KalVista Pharmaceuticals' earnings last quarter? KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) posted its quarterly earnings results on Thursday, September, 5th. The specialty pharmaceutical company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.04. Who are KalVista Pharmaceuticals' major shareholders? Top institutional investors of KalVista Pharmaceuticals include Great Point Partners LLC (3.17%), First Turn Management LLC (2.51%), Emerald Advisers LLC (1.51%) and Driehaus Capital Management LLC (1.27%). Insiders that own company stock include Venrock Healthcare Capital Par, Benjamin L Palleiko, Thomas Andrew Crockett, Christopher Yea, Paul K Audhya, Edward P Feener and Albert Cha. View institutional ownership trends. How do I buy shares of KalVista Pharmaceuticals? Shares of KALV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of KalVista Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that KalVista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV) and Aldeyra Therapeutics (ALDX). This page (NASDAQ:KALV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts